NCT02501603View on ClinicalTrials.gov

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 20, 2022

Conditions
Gastric CancerGastroesophageal Junction Cancer
Interventions
DRUG

afatinib

Afatinib 40mg daily oral administration

DRUG

paclitaxel

Paclitaxel 80mg/m2 IV weekly (day 1,8,15)

Trial Locations (1)

120-752

Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02501603 - Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter